Get started
Author

Emil Andreas Asprusten

Observed names: Emil A Asprusten, Emil A. Asprusten, Emil Asprusten
ORCID: 0009-0005-9075-3296
Observed ORCID: 0009-0005-9075-3296
OpenAlex ID: A5001525341
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
2022 · Peter Rossing, Stefan D. Anker, et al. · Diabetes Care · 242
PDF
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis
2023 · Rajiv Agarwal, Wanzhu Tu, et al. · Annals of Internal Medicine · 125
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial
2025 · Christie M. Ballantyne, Laura Gellis, et al. · JAMA · 81
PDF
Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial
2023 · Frederick Raal, Nyda Fourie, et al. · European Heart Journal · 81
PDF
A sterol panel for rare lipid disorders: sitosterolemia, cerebrotendinous xanthomatosis and Smith-Lemli-Opitz syndrome
2024 · Alexander Bauer Westbye, Lili L. Dizdarevic, et al. · Journal of Lipid Research · 11
PDF
Missense mutation Q384K in the APOB gene affecting the large lipid transfer module of apoB reduces the secretion of apoB-100 in the liver without reducing the secretion of apoB-48 in the intestine
2023 · Thea Bismo Strøm, Emil Asprusten, et al. · Journal of clinical lipidology · 6
PDF
Abstract 15073: Response to PCSK9 Inhibition in Homozygous Familial Hypercholesterolemia Patients is Variable in Different Regions of the World and According to Age
2023 · Frederick J Raal, Vimal Mehta, et al. · Circulation · 3
High levels of lipoprotein(a) – assessment and treatment
2022 · Tone Svilaas, Tor Ole Klemsdal, et al. · Tidsskrift for Den norske legeforening · 3
PDF
Pooled Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, Across Two Phase 3 Trials: CORALreef Lipids and CORALreef HeFH
2026 · Christie Ballantyne, Elina Mikhailova, et al. · Journal of clinical lipidology · 1
Cardiovascular disease and compliance with lipid-lowering therapy among young individuals with familial hypercholesterolemia in Norway – A register study
2025 · Gisle Langslet, Emil A. Asprusten, et al. · American Journal of Preventive Cardiology · 1
Randomized, open-label, study comparing efficacy and safety of lerodalcibep to inclisiran in patients with CVD or at high risk for CVD requiring additional LDL-cholesterol reduction
2024 · Ulrich Laufs, Manuela Licka, et al. · Atherosclerosis · 1
PDF
Abstract 9092: Long-Term Efficacy and Safety of Enlicitide in an Open-Label Extension Study
2026 · Christie Ballantyne, Johnathan Parham, et al. · Circulation
26-a-16905-acc Long-term Efficacy and Safety of Lerodalcibep, a Novel Third Generation Pcsk9 Inhibitor, in the Open-label 72-week Extension Study of Subjects Completing the Phase 3 Studies
2026 · David Kallend, Nyda Fourie, et al. · Journal of the American College of Cardiology
PDF
Eleven Years Follow-up of 1351 Young Fh-individuals in Norway
2024 · Gisle Langslet, Emil Andreas Asprusten, et al. · Atherosclerosis
Rettelse: Høyt nivå av lipoprotein(a) – utredning og behandling
2023 · Tone Svilaas, Tor Ole Klemsdal, et al. · Tidsskrift for Den norske legeforening
PDF
Works count: 15
Citation count: 555
H-index: 6
I10-index: 5
Year
Topic
Type